Drugs / PF-08046032
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06870487 | May 2025 → Apr 2026 | classic Hodgkin lymphoma, diffuse large B-cell lymphoma, head and neck squamous cell carcinoma, melanoma +2 | Pfizer | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-08046032 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06870487 ↗ |
| Route | Intravenous | “PF-08046032 will be administered intravenously (IV) infusion.” NCT06870487 ↗ |